Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Curated Information Page
PubMed Id: 14623889 
This page summarizes selected information from the article referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2012,40:D261-70). To learn more about the scope of PhosphoSitePlus®, click here.
Information from this record has been curated, but not yet edited in PhosphoSitePlus® and may be incomplete.
Kim S, Jin J, Kunapuli SP (2004) Akt activation in platelets depends on Gi signaling pathways. J Biol Chem 279, 4186-95 14623889
Only sites from this record are displayed on this page. Click on the protein name to open the protein page, and on the RSD number to open the site page. For the complete dataset, click the download button, on the right.
Download Sites

T308-p - Akt1 (human)
Orthologous residues
Akt1 (human): T308‑p, Akt1 (mouse): T308‑p, Akt1 (rat): T308‑p, Akt1 (fruit fly): T423‑p, Akt1 (cow): T308‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody
 Relevant cell lines - cell types - tissues:  platelet-blood
 Cellular systems studied:  primary cells
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
thrombin increase
GF109203X thrombin inhibit treatment-induced increase
LY294002 thrombin inhibit treatment-induced increase
BAPTA-AM thrombin inhibit treatment-induced increase
phorbol ester increase
AR-C69931MX thrombin inhibit treatment-induced increase
PAR1-activating peptide increase
PAR4-activating peptide increase
AR-C69931MX PAR1-activating peptide inhibit treatment-induced increase
AR-C69931MX PAR4-activating peptide inhibit treatment-induced increase
GF109203X PAR1-activating peptide inhibit treatment-induced increase
GF109203X PAR4-activating peptide inhibit treatment-induced increase
LY294002 PAR1-activating peptide inhibit treatment-induced increase
LY294002 PAR4-activating peptide inhibit treatment-induced increase
BAPTA-AM PAR1-activating peptide inhibit treatment-induced increase
BAPTA-AM PAR4-activating peptide inhibit treatment-induced increase
thrombin increase
GF109203X thrombin inhibit treatment-induced increase
LY294002 thrombin inhibit treatment-induced increase
BAPTA-AM thrombin inhibit treatment-induced increase
phorbol ester increase
AR-C69931MX thrombin inhibit treatment-induced increase
PAR1-activating peptide increase
PAR4-activating peptide increase
AR-C69931MX PAR1-activating peptide inhibit treatment-induced increase
AR-C69931MX PAR4-activating peptide inhibit treatment-induced increase
GF109203X PAR1-activating peptide inhibit treatment-induced increase
GF109203X PAR4-activating peptide inhibit treatment-induced increase
LY294002 PAR1-activating peptide inhibit treatment-induced increase
LY294002 PAR4-activating peptide inhibit treatment-induced increase
BAPTA-AM PAR1-activating peptide inhibit treatment-induced increase
BAPTA-AM PAR4-activating peptide inhibit treatment-induced increase
Downstream Regulation
 Effect of modification (function):  enzymatic activity, induced

S473-p - Akt1 (human)
Orthologous residues
Akt1 (human): S473‑p, Akt1 (mouse): S473‑p, Akt1 (rat): S473‑p, Akt1 (fruit fly): S586‑p, Akt1 (cow): S473‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody
 Relevant cell lines - cell types - tissues:  platelet-blood
 Cellular systems studied:  primary cells
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
thrombin increase
GF109203X thrombin inhibit treatment-induced increase
LY294002 thrombin inhibit treatment-induced increase
BAPTA-AM thrombin inhibit treatment-induced increase
phorbol ester increase
AR-C69931MX thrombin inhibit treatment-induced increase
PAR1-activating peptide increase
PAR4-activating peptide increase
AR-C69931MX PAR1-activating peptide inhibit treatment-induced increase
AR-C69931MX PAR4-activating peptide inhibit treatment-induced increase
GF109203X PAR1-activating peptide inhibit treatment-induced increase
GF109203X PAR4-activating peptide inhibit treatment-induced increase
LY294002 PAR1-activating peptide inhibit treatment-induced increase
LY294002 PAR4-activating peptide inhibit treatment-induced increase
BAPTA-AM PAR1-activating peptide inhibit treatment-induced increase
BAPTA-AM PAR4-activating peptide inhibit treatment-induced increase
Downstream Regulation
 Effect of modification (function):  enzymatic activity, induced

T308-p - Akt1 (mouse)
Orthologous residues
Akt1 (human): T308‑p, Akt1 (mouse): T308‑p, Akt1 (rat): T308‑p, Akt1 (fruit fly): T423‑p, Akt1 (cow): T308‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody
 Relevant cell lines - cell types - tissues:  platelet-blood
 Cellular systems studied:  primary cells
 Species studied:  mouse
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
thrombin increase
GF109203X thrombin inhibit treatment-induced increase
LY294002 thrombin inhibit treatment-induced increase
BAPTA-AM thrombin inhibit treatment-induced increase
phorbol ester increase
AR-C69931MX thrombin inhibit treatment-induced increase
PAR1-activating peptide increase
PAR4-activating peptide increase
AR-C69931MX PAR1-activating peptide inhibit treatment-induced increase
AR-C69931MX PAR4-activating peptide inhibit treatment-induced increase
GF109203X PAR1-activating peptide inhibit treatment-induced increase
GF109203X PAR4-activating peptide inhibit treatment-induced increase
LY294002 PAR1-activating peptide inhibit treatment-induced increase
LY294002 PAR4-activating peptide inhibit treatment-induced increase
BAPTA-AM PAR1-activating peptide inhibit treatment-induced increase
BAPTA-AM PAR4-activating peptide inhibit treatment-induced increase
Downstream Regulation
 Effect of modification (function):  enzymatic activity, induced

S473-p - Akt1 (mouse)
Orthologous residues
Akt1 (human): S473‑p, Akt1 (mouse): S473‑p, Akt1 (rat): S473‑p, Akt1 (fruit fly): S586‑p, Akt1 (cow): S473‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody
 Relevant cell lines - cell types - tissues:  platelet-blood
 Cellular systems studied:  primary cells
 Species studied:  mouse
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
thrombin increase
GF109203X thrombin inhibit treatment-induced increase
LY294002 thrombin inhibit treatment-induced increase
BAPTA-AM thrombin inhibit treatment-induced increase
phorbol ester increase
AR-C69931MX thrombin inhibit treatment-induced increase
PAR1-activating peptide increase
PAR4-activating peptide increase
AR-C69931MX PAR1-activating peptide inhibit treatment-induced increase
AR-C69931MX PAR4-activating peptide inhibit treatment-induced increase
GF109203X PAR1-activating peptide inhibit treatment-induced increase
GF109203X PAR4-activating peptide inhibit treatment-induced increase
LY294002 PAR1-activating peptide inhibit treatment-induced increase
LY294002 PAR4-activating peptide inhibit treatment-induced increase
BAPTA-AM PAR1-activating peptide inhibit treatment-induced increase
BAPTA-AM PAR4-activating peptide inhibit treatment-induced increase
Downstream Regulation
 Effect of modification (function):  enzymatic activity, induced


Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.